ODVCX | VEMIX | ODVCX / VEMIX | |
Total Expense Ratio | 2.03 | 0.09 | 2,256% |
Annual Report Gross Expense Ratio | 2.03 | 0.09 | 2,256% |
Fund Existence | 29 years | 25 years | - |
Gain YTD | 11.649 | 13.408 | 87% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 14B | 124B | 11% |
Annual Yield % from dividends | 0.00 | 2.79 | - |
Returns for 1 year | 4.99 | 14.07 | 35% |
Returns for 3 years | 22.25 | 33.07 | 67% |
Returns for 5 years | -4.64 | 29.98 | -15% |
Returns for 10 years | 17.59 | 48.86 | 36% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XPH | 42.62 | 0.35 | +0.83% |
SPDR® S&P Pharmaceuticals ETF | |||
AMDG | 20.47 | 0.10 | +0.49% |
Leverage Shares 2X Long AMD Daily ETF | |||
IBB | 131.74 | 0.56 | +0.43% |
iShares Biotechnology ETF | |||
ZALT | 31.08 | 0.06 | +0.19% |
Innovator U.S. Equity 10 Buffr ETF - Qt | |||
AAPB | 21.04 | 0.02 | +0.10% |
GraniteShares 2x Long AAPL Daily ETF |